- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.05. | Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet | 1 | Zacks | ||
| 07.05. | Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade | 1 | Zacks | ||
| 05.05. | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.05. | Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights | 307 | GlobeNewswire (Europe) | NXP900 Phase 1b clinical program continues to enroll patients at select sites in the USNXP900 preclinical presentations at the 2026 American Association for Cancer Research ("AACR") Annual Meeting"... ► Artikel lesen | |
| NUVECTIS PHARMA Aktie jetzt für 0€ handeln | |||||
| 05.05. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting | 1 | GlobeNewswire (USA) | ||
| 11.02. | Nuvectis Pharma GAAP EPS of -$1.32 | 1 | Seeking Alpha | ||
| 11.02. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.02. | Nuvectis Pharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 11.02. | Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights | 195 | GlobeNewswire (Europe) | FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative... ► Artikel lesen | |
| 17.12.25 | Nuvectis startet Phase-1b-Studie zur Kombination von NXP900 mit Osimertinib bei Lungenkrebs | 2 | Investing.com Deutsch | ||
| 17.12.25 | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC | 208 | GlobeNewswire (Europe) | Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the... ► Artikel lesen | |
| 11.08.25 | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 | 579 | GlobeNewswire (Europe) | The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination... ► Artikel lesen | |
| 05.08.25 | Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights | 432 | GlobeNewswire (Europe) | NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers... ► Artikel lesen | |
| 31.07.25 | Nuvectis Pharma, Inc.: Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study | 270 | GlobeNewswire (Europe) | Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,720 | +0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,28 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,520 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| BEAM THERAPEUTICS | 29,370 | -0,10 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,190 | -0,15 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOCARDIA | 1,070 | +3,88 % | BioCardia Shares Surge 48% After FDA Feedback Supports Potential CardiAMP Approval Pathway |
NUVECTIS PHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 9,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NUVECTIS PHARMA INC finden Sie auf Wallstreet Online.